Girendra Kumar Gautam

Dr. Girendra Kumar Gautam

Shri Ram College of Pharmacy, Muzaffarnagar, Muzaffarnagar, Uttar Pradesh, International
orcid
Founder Secretary General, Pharmaceutical Educational Societ...

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2022 in Current Diabetes Reviews
Verified
Journal Article
Closed access
PDF file
AVAKASH VED
AKASH VED
Nadeem RaisNadeem Rais
Nadeem Rais
RARizwan Ahmad
Rizwan Ahmad
KPKehkashan Parveen
Kehkashan Parveen
Girendra Kumar GautamGirendra Kumar Gautam
Girendra Kumar Gautam
ASAkhand Pratap Singh
Akhand Pratap Singh
: The aim of the present study was to review the streptozotocin-nicotinamide (STZ-NA) diabetes model. Type 2 diabetes is more prevalent (90-95%) in adults than type 1. Experimentally- induced diabetes models may be established by chemicals, viral agents, insulin antibodies, surgery, etc. The most advisable and prompt method to induce diabetes is using chemicals, and STZ and alloxan are widely used chemicals. STZ has proven to be a better diabetogenic agent than alloxan because alloxan has many drawbacks, as it induces only type 1 diabetes, has a high mortality rate in rats, and causes ketosis in animals. Moreover, it has lesser selectivity towards β-cells, and the diabetes-induced is reversible. STZ can be used to induce both type 1 and type 2 diabetes. It is noted that the genotoxic behavior of STZ in animals is accomplished through a reduction of nicotinamide adenine dinucleotide (NAD+) in pancreatic β-cells via the GLUT2 (Glucose transporter 2), which can cause cellular damage by DNA (Deoxyribonucleic acid) strand breaks that lead to cell death. NA is a biochemical precursor of NAD+, and it is a poly-ADP-ribose-polymerase-1 (PARP- 1) inhibitor. NAD+ is an important redox reaction co-enzyme for the production of adenosine triphosphate (ATP) and many other metabolic pathways. Extreme DNA damage contributes to the over-activation of PARP-1, loss of cellular resources, and necrotic cells death. Some studies have expressed that NA can protect pancreatic β-cells against the severe cytotoxicity of STZ. The review concluded that the STZ-NA model is dependent on the competency of NA to attain partial protection against the β-cytotoxic essence of STZ to induce type-2 diabetes.

15 August 2023 in Gels
Verified
Journal Article
Open access
PDF file
ABAmit Budhori
Amit Budhori
Abhishek TiwariAbhishek Tiwari
Abhishek Tiwari
VTVarsha Tiwari
Varsha Tiwari
ASAjay Sharma
Ajay Sharma
MKManish Kumar
Manish Kumar
RMRamzi Mothana
Ramzi Mothana
Traditional otic drug delivery methods lack controlled release capabilities, making reverse gelatination gels a promising alternative. Reverse gelatination gels are colloidal systems that transition from a sol to a gel phase at the target site, providing controlled drug release over an extended period. Thermosensitive norfloxacin reverse gelatination gels were developed using a Quality by Design (QbD)-based optimization approach. The formulations were evaluated for their in vitro release profile, rheological behavior, visual appearance, pH, gelling time, and sol–gel transition temperature. The results show that the gelation temperatures of the formulations ranged from 33 to 37 °C, with gelling durations between 35 and 90 s. The drug content in the formulations was uniform, with entrapment efficiency ranging from 55% to 95%. Among the formulations, F10 exhibited the most favorable properties and was selected for a stability study lasting 60 days. Ex-vivo release data demonstrate that the F10 formulation achieved 95.6percentage of drug release at 360 min. This study successfully developed thermosensitive norfloxacin reverse gelatination gels using a QbD-based optimization approach. The selected formulation, F10, exhibited desirable properties in terms of gelling temperature, drug content, and release profile. These gels hold potential for the controlled delivery of norfloxacin in the treatment of ear infections.

12 June 2020 in International Journal of Pharmaceutical Investigation
Verified
Journal Article
Closed access
PDF file
SAShivendra Agarwal
Shivendra Agarwal
Girendra Kumar GautamGirendra Kumar Gautam
Girendra Kumar Gautam
Objectives: The main objective of the present investigation was to develop transdermal delivery of Atorvastatin, a HMG-CoAreductase inhibitor used in the treatment of congestive heart failure (CHF). Atorvastatin was formulated into ethosomal formulation to reduce the first pass metabolism and increase the systemic bioavailability. Methods: Cold method was used to formulate ethosomes by using suitable phosphatidylcholine and permeation enhancer. All the formulation were characterized for vesicle morphology, particle size and entrapment efficiency by Transmission Electron Microscopy, Differential light scattering and centrifugation respectively. The effect of different formulation variable on skin permeation of Atorvastatin was studied via synthetic semipermeable membrane or skin of new born mice by using diffusion cell. Results: The optimized ethosomal formulation showed enhanced drug delivery with no first pass metabolism, entrapment efficiency was found to be 98.65 ± 0.63% and showed drug release 98.13 ± 3.67% for ethosomal formulation across rat skin as compared to 52.37 ± 3.62% for hydroethanolic solution. Conclusion: Finally it was concluded from the study that, ethosomes can increase the transdermal flux, prolong the release and present an attractive route for sustained delivery of Atorvastatin.

15 December 2018 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
SKSarita Karole
Sarita Karole
Girendra Kumar GautamGirendra Kumar Gautam
Girendra Kumar Gautam
SGShailesh Gupta
Shailesh Gupta
Bombax ceiba L is a big deciduous tree found in tropical and subtropical regions of Asia, Africa and Australia. Conventional systems of medicine such as Ayurveda, Siddha and Unani have been highlighted the use of B. ceiba parts (bark, leaves and flower) for the treatment of manydiseases like hypertension, HIV infections, inflammation, catarrhal affection, ulcer, acne, gynecological disorders, fever, dysentery, algesia, hepatotoxicity, piles and urinary infections. The aim of the present study was to evaluate pharmacognostic, physicochemical, qualitative and quantitative phytochemical analysis of leaf and bark of B. ceiba collected from Bhopal region of Madhya Pradesh. The pharmacognostic studies out in terms of various investigations like organoleptic or morphological characters, microscopic or anatomical studies, physicochemical evaluations (loss on drying, ash value, extractive values and acid insoluble ash value). Qualitative analysis of various phytochemical constituents and quantitative analysis of total phenolics and flavonoids were determined by the well-known test protocol available in the literature. The detail microscopy of bark revealed the presence of cork cell, lignified fibre, calcium oxalate crystals, xylem vessels. Physiochemical parameters such as percentage of foreign matters, ash values, loss on drying swelling index, extractive values were determined. Phytochemical analysis revealed the presence of phenols, flavonoids, tannins, alkaloids and glycosides. In the procedure of quantitative analysis of flavonoids and phenolic compound was carried out by aluminium chloride Folins and Ciocalteau reagent method .In this methodthe totalflavonoids content and phenolic content of B. ceiba ethanolic and aqueous barks extracts was found to be 6.272, 3.363 and 2.607, 1.607mg /100mg respectively and total phenolic and flavonoids content of B. ceiba ethanolic, aqueous leaves extracts was found to be 7.381, 4.590 and 3.200, 1.792 mg/100mg respectively. These information will also be helpful to differentiate B. ceiba from the closely related other species. The diverse array of phytochemicals present in the plant thus suggests its therapeutic potentials which may be explored in drug manufacturing industry as well as in traditional medicine.

1 February 2018 in Asian Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
HSHarjeet Singh
Harjeet Singh
Ram DayalRam Dayal
Ram Dayal
Girendra Kumar GautamGirendra Kumar Gautam
Girendra Kumar Gautam

15 February 2019 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
NKNeelam Khan
Neelam Khan
Girendra Kumar GautamGirendra Kumar Gautam
Girendra Kumar Gautam
AGArun K. Gupta
Arun K. Gupta
Diabetes mellitus is a metabolic disorder characterized by hyperglycemia resulting long-term secondary complication. Aldose reductase, the rate-limiting enzyme of the polyol pathway, plays a key role in the treatment of diabetic complications. Appropriately, inhibition of this enzyme is emerging as a major therapeutic strategy for the pathogenesis of secondary complication. In this study, we describe a series of 5 aryl benzylidene -thiazolidine, 4-dione derivatives, F3 synthesized as aldose reductase inhibitors. Besides inhibiting efficiently the target enzyme, F4 and F5 showed additional AR inhibitory as well as hypoglycaemic activity (146.15 and 175.20 mg/dl ) thus emerging as novel dual acting compounds. The bezylidene derivative F3, the most promising of the whole series, showed a well-balanced, consisting of ALR2 inhibitory efficacy (83.00% at 10µg/mL), similarly, F3 have lower blood glucose level in the range of 131.11 mg/dl at 15 mg/kg body weight. This compound show robust in vitro and in vivo efficacy, and could be considered as promising dual target antidiabetic drug candidates. Keywords: Diabetes mellitus, hyperglycemia, Aldose reductase inhibitors